Sánchez Benavides, GonzaloSalvadó, GemmaArenaza Urquijo, Eider M.Grau-Rivera, OriolSuárez-Calvet, MarcMilà Alomà, MartaGonzález de Echávarri, José MariaMinguillón, CarolinaCrous-Bou, MartaNiñerola-Baizán, AidaPerissinotti, AndrésGispert López, Juan DomingoMolinuevo, José LuisALFA Study2021-05-182021-05-182020Sánchez-Benavides G, Salvadó G, Arenaza-Urquijo EM, Grau-Rivera O, Suárez-Calvet M, Milà-Alomà M, et al. Quantitative informant‐ and self‐reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4. Alzheimers Dement (Amst). 2020 Nov 11; 12(1): e12127. DOI: 10.1002/dad2.121272352-8729http://hdl.handle.net/10230/47574Introduction: Amyloid beta (Aβ) pathology is an Alzheimer's disease early hallmark. Here we assess the value of longitudinal self- and informant reports of cognitive decline to predict Aβ positron emission tomography (PET) outcome in cognitively unimpaired middle-aged individuals. Methods: A total of 261 participants from the ALFA+ study underwent [18F]flutemetamol PET and Subjective Cognitive Decline Questionnaire (SCD-Q) concurrently, and 3 years before scan. We used logistic regressions to evaluate the ability of SCD-Q scores (self and informant) to predict Aβ PET visual read, and repeated analysis of variance to assess whether changes in SCD-Q scores relate to Aβ status. Results: Self-perception of decline in memory (odds ratio [OR] = 1.2), and informant perception of executive decline (OR = 1.6), increased the probability of a positive scan. Informant reports 3 years before scanning predicted Aβ PET outcome. Longitudinal increase of self-reported executive decline was predictive of Aβ in women (P = .003). Discussion: Subjective reports of cognitive decline are useful to predict Aβ and may improve recruitment strategies.application/pdfengCopyright © 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1002/dad2.12127Alzheimer's diseaseAmyloidInformant reportsPreclinicalSubjective cognitive declineinfo:eu-repo/semantics/openAccess